Nelpa Lifesciences Inc Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: Nelpa Lifesciences Inc Pharmaceutical Import Records from India — 11 Products, $13.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Nelpa Lifesciences Inc — Pharmaceutical Importer Profile (2026) | 11 Products, $13.3M Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Nelpa Lifesciences Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Bdh Healthcare Private Limited	$4.7M	388	20.8%
Bdh Industries Limited	$4.7M	278	20.8%
Vins International Private Limited	$3.0M	298	13.0%
Fortcaps Laboratories Private Limited	$2.0M	172	8.8%
Deepa International	$1.8M	107	8.0%
Shreeji Impex	$1.4M	108	6.0%
Kilitch Drugs (india) Limited	$1.1M	55	4.7%
Bruck Pharma Private Limited	$997.7K	84	4.4%
Pesino Pharmaceuticals Private Limited	$945.4K	37	4.2%
Enicar Pharmaceuticals Private Limited	$889.5K	82	3.9%
Althea Pharma Private Limited	$714.1K	190	3.1%
Kilitch Drugs India Limited	$533.0K	19	2.3%

Nelpa Lifesciences Inc sources from 12 verified Indian suppliers across 1,053 distinct formulations. The supply base is diversified across 12 suppliers, reducing single-source dependency risk.

What Formulations Does Nelpa Lifesciences Inc Import?

Formulation	Value	Ships
Pharmaceutical products- pipetasaph-4.5GM (piperacillin 4g+tazobactam 500MG powder for injection USP	$271.1K	16
Megyxan 500 (mefenamic acid 500 MG	$201.8K	10
Pharmaceutical products moxeth amoxicillin capsule BP 500 MG	$200.0K	4
Pharmaceutical products-saphormin t	$158.9K	9
Pharmaceutical products- saphormin t	$156.1K	7
Pharmaceutical products-harmless medicine-saphmox 500 capsule amoxicillin BP 500 MG capsules ( 100860 1010c)	$150.0K	3
Pharmaceutical products-harmless medicine for human consumption saphteride-5 (finasteride tablets USP 5 MG)

What Products Does Nelpa Lifesciences Inc Import?

Top Products by Import Value

1Losartan$4.2M 2Celecoxib$3.4M 3Potassium$2.3M 4Vitamin$900.0K 5Zinc$800.0K 6Amino$600.0K

Import Portfolio — Top 11 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Losartan	Cardiovascular	$4.2M	83	1.4%	3
2	Celecoxib	Analgesics & Antipyretics	$3.4M	68	2.5%

Key Metrics

Total Import Value$13.3M

Products11

Shipments284

Categories7

CountryPhilippines

#1 Rankings0

Indian Suppliers12

Formulations1,053

Top Categories

Cardiovascular31.2%

Nutritional Supplements29.3%

Last updated: March 28, 2026

Nelpa Lifesciences Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Nelpa Lifesciences Inc is a pharmaceutical importer and wholesaler based in the Philippines, specializing in the procurement and distribution of finished pharmaceutical formulations. The company is headquartered in Muntinlupa, Manila, at Unit 305, Venture Building, Madrigal Business Park. Established in 2009, Nelpa Lifesciences Inc has been actively involved in the Philippine pharmaceutical supply chain, focusing on importing a diverse range of pharmaceutical products from international suppliers. The company's operations are guided by its License to Operate (LTO) issued by the Philippine Food and Drug Administration (FDA), which authorizes it to import and distribute pharmaceutical products within the country. (verification.fda.gov.ph)

2Distribution Network

Nelpa Lifesciences Inc's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across the Philippines. While specific warehouse locations are not publicly disclosed, the company's central office in Muntinlupa serves as a key hub for operations. The company leverages a robust logistics infrastructure to manage the importation and distribution of pharmaceutical products, ensuring timely and reliable delivery to various regions within the country. This logistical capability is crucial for maintaining a steady supply of essential medications to meet the demands of the Philippine healthcare market.

Supplier Relationship Intelligence — Nelpa Lifesciences Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Nelpa Lifesciences Inc exhibits a high degree of sourcing concentration, with a significant portion of its pharmaceutical imports originating from India. The company's total import value from India amounts to $13.3 million USD, encompassing 284 shipments across 11 products in 7 therapeutic categories. This concentration indicates a strategic choice to leverage India's established pharmaceutical manufacturing capabilities, ensuring a consistent supply of quality products. The stability of this sourcing relationship is evidenced by the consistent volume of shipments over the years, reflecting a reliable and ongoing partnership between Nelpa Lifesciences Inc and its Indian suppliers.

2Supply Chain Resilience

Nelpa Lifesciences Inc's supply chain resilience is bolstered by its diversified portfolio of 1,053 unique pharmaceutical formulations sourced from 12 verified Indian suppliers. This diversity mitigates risks associated with dependency on a single supplier or product line. The company's strategic sourcing from multiple suppliers enhances its ability to adapt to potential disruptions in the supply chain, ensuring a continuous flow of pharmaceutical products to meet market demands. Additionally, the company's adherence to regulatory compliance standards, as evidenced by its LTO issued by the Philippine FDA, underscores its commitment to maintaining a robust and resilient supply chain. (verification.fda.gov.ph)

3Strategic Implications

The sourcing pattern of Nelpa Lifesciences Inc, characterized by a concentrated focus on Indian suppliers, positions the company to benefit from India's competitive pricing and established manufacturing standards. This strategic alignment allows Nelpa Lifesciences Inc to offer a diverse range of pharmaceutical products at competitive prices within the Philippine market. For Indian exporters, this presents an opportunity to strengthen existing partnerships and explore avenues for expanding their product offerings to meet the evolving needs of Nelpa Lifesciences Inc. By aligning with the company's sourcing strategy, Indian exporters can enhance their market presence and contribute to the sustained growth of the Philippine pharmaceutical sector.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

The primary regulatory authority overseeing pharmaceutical imports in the Philippines is the Food and Drug Administration (FDA), operating under the Department of Health (DOH). The FDA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products entering the country. Key legislation governing pharmaceutical imports includes the Food, Drugs, and Devices Act (Republic Act No. 3720), which mandates the registration of all drugs and medicines, and the FDA Act of 2009 (Republic Act No. 9711), which established the FDA's authority and operational framework. The registration pathway for pharmaceutical products involves submitting applications to the FDA, providing comprehensive product information, and undergoing evaluation to obtain marketing authorization. This regulatory framework ensures that imported pharmaceutical products meet the required standards for public health and safety. (respicio.ph)

2Import Licensing & GMP

Import licensing in the Philippines is governed by the FDA, which issues Licenses to Operate (LTO) to entities involved in the importation and distribution of pharmaceutical products. To obtain an LTO, companies must demonstrate compliance with regulatory requirements, including adherence to Good Manufacturing Practice (GMP) standards. The FDA recognizes GMP certificates from reputable authorities, such as the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), facilitating the importation of pharmaceutical products that meet international quality standards. Additionally, wholesale distribution authorization is granted to entities that meet the FDA's criteria, ensuring that imported pharmaceutical products are distributed through channels that uphold quality and safety standards. (respicio.ph)

3Quality & Labeling

Imported pharmaceutical products in the Philippines are subject to stringent quality control measures, including batch testing and stability assessments, to ensure their safety and efficacy. Labeling requirements mandate that product information be presented in English and Filipino, providing clear instructions and information to consumers and healthcare professionals. Serialization mandates are enforced to enhance traceability and prevent counterfeit products from entering the market, thereby safeguarding public health and maintaining the integrity of the pharmaceutical supply chain. (respicio.ph)

4Recent Regulatory Changes

Between 2024 and 2026, the Philippines implemented several regulatory changes affecting pharmaceutical imports. Notably, in August 2024, the Department of Health issued Administrative Order No. 2024-0012, outlining guidelines for the registration of pharmaceutical products and Active Pharmaceutical Ingredients (APIs) intended exclusively for export. This order established procedures for the registration process of export-only pharmaceutical products and APIs, aiming to streamline the exportation of pharmaceutical goods. Additionally, in November 2025, the Philippines published new pharmaceutical regulations, including implementing guidelines for the World Health Organization (WHO) Collaborative Procedure on the Registration of Pharmaceutical Products Approved by Stringent Regulatory Authorities (SRAs) and the classification of pharmaceutical products intended for human use. These regulations aim to enhance the efficiency and effectiveness of the pharmaceutical registration process, ensuring that imported products meet international standards.

TransData Nexus Research · Philippines regulatory databasesMar 2026

Nelpa Lifesciences Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Nelpa Lifesciences Inc's product strategy focuses on importing pharmaceutical products across various therapeutic categories, with a significant emphasis on cardiovascular medications, nutritional supplements, and analgesics & antipyretics. This strategic focus aligns with the prevalent health concerns in the Philippines, such as cardiovascular diseases, nutritional deficiencies, and the need for effective pain management solutions. The company's importation of these specific therapeutic areas is driven by market demand and the necessity to provide accessible and effective treatments to the Filipino population. By concentrating on these categories, Nelpa Lifesciences Inc addresses critical healthcare needs and contributes to the overall well-being of the community.

2Sourcing Profile

Nelpa Lifesciences Inc's sourcing strategy is centered on procuring generic pharmaceutical formulations from India, capitalizing on the country's robust pharmaceutical manufacturing sector. The company's preference for generic drugs allows it to offer cost-effective alternatives to branded medications, making essential treatments more accessible to a broader segment of the Philippine population. India's compliance with international quality standards, such as WHO GMP and PIC/S certifications, ensures that the imported formulations meet the required safety and efficacy benchmarks. This sourcing approach enables Nelpa Lifesciences Inc to maintain a diverse and high-quality product portfolio that caters to the varied healthcare needs of the market.

3Market Positioning

Based on its product mix, Nelpa Lifesciences Inc serves multiple segments of the Philippine pharmaceutical market, including retail pharmacies, hospitals, government tenders, and wholesale distribution channels. The company's importation of a wide range of pharmaceutical products allows it to supply medications to various healthcare providers and institutions, ensuring that essential treatments are available across different sectors. By positioning itself as a versatile supplier, Nelpa Lifesciences Inc plays a crucial role in enhancing the accessibility and availability of pharmaceutical products throughout the Philippines.

TransData Nexus Research · DGFT trade data analysisMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Nelpa Lifesciences Inc identified across shipments using consignee name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Nelpa Lifesciences Inc's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 284 individual customs records matching Nelpa Lifesciences Inc.
5.Supplier Verification: Nelpa Lifesciences Inc sources from 12 verified Indian suppliers across 1,053 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

11 Products Tracked

7 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Nelpa Lifesciences Inc

Nelpa Lifesciences Inc — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Nelpa Lifesciences Inc?

What Formulations Does Nelpa Lifesciences Inc Import?

What Products Does Nelpa Lifesciences Inc Import?

Top Products by Import Value

Import Portfolio — Top 11 by Import Value

Key Metrics

Top Categories

Nelpa Lifesciences Inc — Corporate Profile & Information

1Company Overview

2Distribution Network

Nelpa Lifesciences Inc Therapeutic Categories — 7 Specializations

Indian Suppliers

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — Nelpa Lifesciences Inc

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into Philippines — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Nelpa Lifesciences Inc — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to Nelpa Lifesciences Inc

1Opportunity Assessment

2Requirements & Qualifications

Frequently Asked Questions — Nelpa Lifesciences Inc

What products does Nelpa Lifesciences Inc import from India?

Who supplies pharmaceuticals to Nelpa Lifesciences Inc from India?

What is Nelpa Lifesciences Inc's total pharmaceutical import value?

What therapeutic categories does Nelpa Lifesciences Inc focus on?

Get Full Nelpa Lifesciences Inc Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology